|
|
Cancer Drug Parity Act Gains Strong Support from Leading Healthcare Organizations
In a significant stride toward ensuring equitable access to cancer treatments, Members of the House of Representatives reintroduced the Cancer Drug Parity Act on Wednesday, November 8. The bill has garnered widespread endorsement from prominent healthcare organizations and patient advocacy groups. The International Myeloma Foundation (IMF), which leads the Coalition to Improve Access to Cancer Care (CIACC), fervently supports the Cancer Drug Parity Act, recognizing its profound impact on myeloma patients and their families. Read the full press release of the IMF and other organizations’ support of the Cancer Drug Parity Act.
|
|
|
|
|
|
|
Clinical Trial of KTX-1001 Is Enrolling Patients
KTX-1001 is an oral, first-in-class, and selective MMSET catalytic inhibitor that suppresses H3k36me2 in patients with relapsed and refractory multiple myeloma (RRMM) with a focus on patients with the t(4;14). K36-MMSET-001 (ClinicalTrials.gov NCT05651932) is a phase I open-label study in patients with RRMM. It is a dose escalation study followed by an expansion cohort in patients with the t(4;14) genetic translocation to evaluate the safety, tolerability, and preliminary efficacy of KTX-1001. This clinical trial is enrolling patients in the United States, Canada, France, and Spain. Translations of the clinical trial fact sheet are available in French and Spanish.
|
|
|
|
|
|
|
Now Available: The Fall 2023 Edition of Myeloma Today
In the Fall 2023 edition, IMF Chief Medical Officer Dr. Joseph Mikhael highlights the approval of two new myeloma drugs. Those drugs, ELREXFIO™ and TALVEY™, are both bispecific monoclonal antibodies, and they offer innovative treatment options for patients with relapsed or refractory myeloma. The edition also features the IMF's M-Power health equity initiative, with a focus on the achievements of Medical Student Scholars and successful educational events held in New York. The IMF’s Nurse Leadership Board's 19th annual meeting is also covered, focusing on collaborations and programs supporting myeloma nurses and empowering patients. The issue includes an article on the crucial role of care partners in helping loved ones live well with myeloma. Lastly, the IMF's 2023 Blood Cancer Awareness Month campaign is recapped, exploring the important question, "Do You Know Myeloma?” Myeloma Today is available to download for FREE.
|
|
|
|
|
|
|
Watch the Replay of the Most Recent IMF Patient and Family Webinar
During this IMF Patient and Family Webinar, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie presented a Myeloma 101. IMF Nurse Leadership Board Member Mary Steinbach, DNP, DPRN, covered managing side effects and complications of myeloma care. Dr. Rafat Abonour focused on frontline treatment options. Finally, Dr. Ajai Chari shed light on relapse and new immune therapies.
|
|
|
|
|
|
|
November Is National Caregivers Month
According to the White House's "Proclamation on National Family Caregivers Month 2023," this month "we honor the Americans who lift up our communities and our Nation by providing dignified, professional, and invaluable care to the people we cherish the most." Read "The Role of the Care Partner in Multiple Myeloma" from the most recent issue of the IMF publication Myeloma Today to learn more. Also, to help you and your loved ones in caring for those living with multiple myeloma, the IMF has created a Care Partner Resource page.
|
|
|
|
|
|
|
Around the Web: Myeloma News
To keep you abreast of the most recent myeloma research findings, “The Myeloma Minute” features links to top myeloma content around the web. For this week, we encourage you to explore this study on real-world effectiveness of Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone. Also, this study explores an additional arm of the ongoing phase 1b/2 STOMP trial. And, in this new study, researchers seek to learn whether early relapse in multiple myeloma is prognostic of early progression and risk. Finally, the 65th American Society of Hematology (ASH) Annual Meeting and Exposition will take place December 9-12, 2023, in San Diego, California, and online. This article discusses the new leadership of ASH. As always, we invite you to visit the IMF Newsroom for the most recent announcements in myeloma news.
|
|
|
|
|
|
|
Medicare Open Enrollment Period Now Active
Medicare's Open Enrollment Period is October 15 - December 7. This timeframe is your chance to explore Medicare Plans and see what works for you. Plans can change from year to year, and your health needs may change, too. The International Myeloma Foundation and our InfoLine team do not have recommendations about Medicare. We do, however, encourage you to explore Medicare.gov, or contact your local State Health Insurance Assistance Program (SHIP) to get the phone number for Medicare assistance for your state.
|
|
|
|
|
|
|
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
What progress towards a myeloma cure and prevention has been made?
|
|
|
|
|
|
Instagram @IMFmyeloma